share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  10/16 05:04

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has reported a material definitive agreement involving its wholly-owned subsidiary, Conduit Pharmaceuticals Limited, and the issuance of a Convertible Promissory Note to Vrezh Isayan and Sharon Lee Isayan. The note, originally due on September 20, 2024, with a principal amount of $800,000 and an interest rate of 20% per annum, was amendable to extend the maturity date to October 20, 2024. The amendment, effective as of September 20, 2024, also allowed for the issuance of $80,000 worth of the company's common stock and 2,000,000 shares to cover accrued interest and principal. The company has the discretion to further extend the repayment date to November 19 or December 19, 2024. On October 11, 2024, Conduit Pharmaceuticals Inc. issued 2,781,250 shares of common stock in fulfillment of the obligations under the amendment. The details of the Convertible Note and the Loan Extension Amendment were filed with the SEC and are included as exhibits in the company's current report.
Conduit Pharmaceuticals Inc. has reported a material definitive agreement involving its wholly-owned subsidiary, Conduit Pharmaceuticals Limited, and the issuance of a Convertible Promissory Note to Vrezh Isayan and Sharon Lee Isayan. The note, originally due on September 20, 2024, with a principal amount of $800,000 and an interest rate of 20% per annum, was amendable to extend the maturity date to October 20, 2024. The amendment, effective as of September 20, 2024, also allowed for the issuance of $80,000 worth of the company's common stock and 2,000,000 shares to cover accrued interest and principal. The company has the discretion to further extend the repayment date to November 19 or December 19, 2024. On October 11, 2024, Conduit Pharmaceuticals Inc. issued 2,781,250 shares of common stock in fulfillment of the obligations under the amendment. The details of the Convertible Note and the Loan Extension Amendment were filed with the SEC and are included as exhibits in the company's current report.
Conduit Pharmaceuticals Inc.报告了一份涉及其全资子公司Conduit Pharmaceuticals Limited的实质性确定协议，并发行了一份可转换的本票给Vrezh Isayan和Sharon Lee Isayan。该票据原定于2024年9月20日到期，本金为80万美元，年利率为20%，经修改将到期日延长至2024年10月20日。该修改自2024年9月20日生效，还允许发行价值8万美元的公司普通股和2,000,000股以支付应计利息和本金。公司有权将还款日期进一步延长至2024年11月19日或12月19日。2024年10月11日，Conduit Pharmaceuticals Inc.发行了2,781,250股普通股以履行修改下的义务。可转换票据及贷款延期修正案的细节已提交给美国证券交易委员会，并作为公司的最新报告中的附件。
Conduit Pharmaceuticals Inc.报告了一份涉及其全资子公司Conduit Pharmaceuticals Limited的实质性确定协议，并发行了一份可转换的本票给Vrezh Isayan和Sharon Lee Isayan。该票据原定于2024年9月20日到期，本金为80万美元，年利率为20%，经修改将到期日延长至2024年10月20日。该修改自2024年9月20日生效，还允许发行价值8万美元的公司普通股和2,000,000股以支付应计利息和本金。公司有权将还款日期进一步延长至2024年11月19日或12月19日。2024年10月11日，Conduit Pharmaceuticals Inc.发行了2,781,250股普通股以履行修改下的义务。可转换票据及贷款延期修正案的细节已提交给美国证券交易委员会，并作为公司的最新报告中的附件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间